Mersana Therapeutics (MRSN) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts MRSN Hot Sheet
Join SI Premium – FREE
Mersana Therapeutics (NASDAQ: MRSN) reported Q2 EPS of ($0.20), $0.03 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $8.72 million.
For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Albany International ends strategic review, keeps Salt Lake City facility
- United Community Banks completes $2B Navitas sale to Wafra
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
